Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022.
Saviuk tells Proactive this marks the 5th consecutive quarter of growth for the company, with adjusted gross profit increasing by 178% to $4.2 million from a year earlier.
Physicians prescribing Enerzair and Atectura reached 1,583 at the end of the first quarter, 39% growth for the quarter and a 799% increase year-over-year. Total annual Enerzair and Atectura prescriptions surpassed 34,000 at the end of 1Q 2023, up 1,917% year-over-year.